MAP2K7 and melanoma: In clinical trials, encorafenib achieved significantly longer progression-free survival and fewer adverse effects on advance melanoma with V600 mutations as both monotherapy and combination therapy with the MEK inhibitor binimetinib, compared with vemurafenib[26,27,142].